Strategic Partnerships Gossamer Bio has established key partnerships with companies like Chiesi Global Rare Diseases, indicating opportunities for collaborative sales strategies and cross-promotional activities with partner networks.
Clinical Trial Updates The ongoing clinical trials, such as the Phase 2 TORREY Study and Phase 3 PROSERA Study, present opportunities to engage with healthcare professionals, institutions, and patients who may benefit from Gossamer Bio's innovative treatments.
Investment Relations Recent investments from entities like SilverArc Capital Management LLC demonstrate investor confidence in Gossamer Bio, potentially opening avenues for engaging with investment firms seeking opportunities in the biotechnology sector.
Expansion Initiatives Gossamer Bio's expansion into developing treatments for various respiratory diseases beyond pulmonary arterial hypertension (PAH) suggests market diversification opportunities to target a broader range of healthcare providers and patient segments.
Expert Leadership Appointment of industry experts like Steven D. Nathan, M.D., and Bob Smith to the Board of Directors and executive team provides an opportunity to leverage their networks and expertise for strategic sales engagements and market positioning.
51
123
$10M$50M
210$10M$50M
65$10M$50M
11$10M
29
32$10M
150$10M$50MGossamer Bio uses 8 technology products and services including WordPress, Backbone.js, Microsoft, and more. Explore Gossamer Bio's tech stack below.
| Gossamer Bio Email Formats | Percentage |
| FLast@gossamerbio.com | 87% |
| FirstLast@gossamerbio.com | 6% |
| First.Last@gossamerbio.com | 5% |
| LFirst@gossamerbio.com | 2% |
Biotechnology ResearchCalifornia, United States51-200 Employees
Gossamer Bio is a San Diego-based clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to enhance the lives of people living with pulmonary hypertension.
Company Overview
Media & News
Funding & FinancialsGossamer Bio has raised a total of $212M of funding over 5 rounds. Their latest funding round was raised on Jul 20, 2023 in the amount of $212M.
Gossamer Bio's revenue is in the range of $10M$50M
Funding & FinancialsGossamer Bio has raised a total of $212M of funding over 5 rounds. Their latest funding round was raised on Jul 20, 2023 in the amount of $212M.
Gossamer Bio's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com